Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric F Morand

Showing results (211-220 of 227) with videos related to

Pageof 23
Sort By:
Nature Medicine|August 9, 2016
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosusJing He, Xia Zhang, Yunbo Wei, et al.
Arthritis Care & Research|July 1, 2021
Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort StudyRangi Kandane-Rathnayake, Worawit Louthrenoo, Shue-Fen Luo, et al.
The Lancet. Rheumatology|January 23, 2024
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort studyKathryn Connelly, Rangi Kandane-Rathnayake, Alberta Hoi, et al.
Annals of the Rheumatic Diseases|February 29, 2024
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort studyYasuhiro Katsumata, Eisuke Inoue, Masayoshi Harigai, et al.
The Lancet. Rheumatology|June 14, 2024
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort studyVera Golder, Rangi Kandane-Rathnayake, Ning Li, et al.
Arthritis Research & Therapy|March 15, 2022
'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort studyRangi Kandane-Rathnayake, Worawit Louthrenoo, Alberta Hoi, et al.
Rheumatology (Oxford, England)|November 18, 2025
Predictors of damage accrual by organ domain in systemic lupus erythematosusRangi Kandane-Rathnayake, Luigi Zolio, JIyoon Choi, et al.
Rheumatology (Oxford, England)|December 10, 2024
Association of lupus low disease activity state and remission with reduced organ damage and flare in systemic lupus erythematosus patients with high disease activity: a multi-national, longitudinal cohort studyRangi Kandane-Rathnayake, Vera Golder, Worawit Louthrenoo, et al.
The Lancet. Rheumatology|January 22, 2024
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort studyJiacai Cho, Liang Shen, Molla Huq, et al.
The Journal of Rheumatology|March 15, 2024
Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus ErythematosusVera Golder, Rangi Kandane-Rathnayake, Worawit Louthrenoo, et al.
Pageof 23

Showing results (211-220 of 227) with videos related to

Sort By:
Pageof 23
Nature Medicine|August 9, 2016
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosusJing He, Xia Zhang, Yunbo Wei, et al.
Arthritis Care & Research|July 1, 2021
Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort StudyRangi Kandane-Rathnayake, Worawit Louthrenoo, Shue-Fen Luo, et al.
The Lancet. Rheumatology|January 23, 2024
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort studyKathryn Connelly, Rangi Kandane-Rathnayake, Alberta Hoi, et al.
Annals of the Rheumatic Diseases|February 29, 2024
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort studyYasuhiro Katsumata, Eisuke Inoue, Masayoshi Harigai, et al.
The Lancet. Rheumatology|June 14, 2024
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort studyVera Golder, Rangi Kandane-Rathnayake, Ning Li, et al.
Arthritis Research & Therapy|March 15, 2022
'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort studyRangi Kandane-Rathnayake, Worawit Louthrenoo, Alberta Hoi, et al.
Rheumatology (Oxford, England)|November 18, 2025
Predictors of damage accrual by organ domain in systemic lupus erythematosusRangi Kandane-Rathnayake, Luigi Zolio, JIyoon Choi, et al.
Rheumatology (Oxford, England)|December 10, 2024
Association of lupus low disease activity state and remission with reduced organ damage and flare in systemic lupus erythematosus patients with high disease activity: a multi-national, longitudinal cohort studyRangi Kandane-Rathnayake, Vera Golder, Worawit Louthrenoo, et al.
The Lancet. Rheumatology|January 22, 2024
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort studyJiacai Cho, Liang Shen, Molla Huq, et al.
The Journal of Rheumatology|March 15, 2024
Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus ErythematosusVera Golder, Rangi Kandane-Rathnayake, Worawit Louthrenoo, et al.
Pageof 23